State Street SPDR S&P Biotech ETF
406 hedge funds and large institutions have $5.44B invested in State Street SPDR S&P Biotech ETF in 2019 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 118 increasing their positions, 136 reducing their positions, and 65 closing their positions.
20.05% more ownership
Funds ownership: 128.13% → 148.18% (+20%)
4% less funds holding
Funds holding: 424 → 406 (-18)
7% less capital invested
Capital invested by funds: $5.82B → $5.44B (-$379M)
13% less repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 136
23% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 65
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
54% less call options, than puts
Call options by funds: $829M | Put options by funds: $1.81B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$220M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$210M |
| 3 |
Citigroup
New York
|
+$162M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$91.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$65.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$272M |
| 2 |
Morgan Stanley
New York
|
-$123M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$73.8M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$54.8M |
| 5 |
Two Sigma Advisers
New York
|
-$43.3M |
XBI Hedge Fund Activity: Q3 2019 in Review
406 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2019, worth a combined $5.44B — down 6.5% from $5.82B a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of XBI and 50 opened new positions — a net loss of 15 holders — while 136 trimmed existing stakes and 118 added.
The largest buyer was JP Morgan Chase, adding an estimated $220M. The largest seller was UBS Group, cutting an estimated $272M.
- 406 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2019, down from 424 in Q2 2019.
- Funds reported $5.44B of State Street SPDR S&P Biotech ETF stock for Q3 2019, down 6.5% quarter-over-quarter.
- 50 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2019 and 65 closed out, a net change of -15 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2019 was JP Morgan Chase, an estimated $220M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2019 was UBS Group, an estimated $272M sold.
Based on aggregated 13F filings for Q3 2019.